Condition: Hairy Cell Leukemia · Sponsor: University of Giessen
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.
This description comes directly from the study's public registry record.
Mathias J Rummel, Prof PhD · +4964198542 · mathias.rummel@innere.med.uni-giessen.de
Juergen Barth · +4964198542 · juergen.barth@innere.med.uni-giessen.de
Always discuss trial participation with your own doctor first.
| Community based hemato-oncology medical office | Ansbach, Germany | Recruiting |
| Community based hemato-oncology medical office | Aschaffenburg, Germany | Recruiting |
| Rhön-Saale-Klinik gGmbH | Bad Neustadt an der Saale, Germany | Recruiting |
| Community based hemato-oncology medical office | Berlin, Germany | Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Community based hemato-oncology medical office | Bremen, Germany | Recruiting |
| Community based hemato-oncology medical office | Celle, Germany | Recruiting |
| Community based hemato-oncology medical office | Cottbus, Germany | Recruiting |
| Community based hemato-oncology medical office | Darmstadt, Germany | Recruiting |
| Community based hemato-oncology medical office | Dresden, Germany | Recruiting |
| Community based hemato-oncology medical office | Duisburg, Germany | Recruiting |
| Klinik Duisburg-West | Duisburg, Germany | Recruiting |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02131753